Research Analysts Offer Predictions for NTLA FY2026 Earnings

Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) – Analysts at HC Wainwright dropped their FY2026 earnings per share estimates for Intellia Therapeutics in a report released on Friday, November 6th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings per share of ($3.24) for the year, down from their prior estimate of ($3.06). HC Wainwright currently has a “Buy” rating and a $25.00 target price on the stock. The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($3.28) per share. HC Wainwright also issued estimates for Intellia Therapeutics’ Q1 2027 earnings at ($0.82) EPS, Q3 2027 earnings at ($0.82) EPS, Q4 2027 earnings at ($0.78) EPS and FY2027 earnings at ($3.17) EPS.

Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) last announced its earnings results on Thursday, November 5th. The company reported ($0.91) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.11). Intellia Therapeutics had a negative return on equity of 64.74% and a negative net margin of 805.75%. The business had revenue of $7.16 million for the quarter, compared to the consensus estimate of $9.74 million. During the same period in the prior year, the business posted ($0.92) earnings per share. The firm’s revenue for the quarter was down 47.8% compared to the same quarter last year.

A number of other equities research analysts also recently issued reports on NTLA. Wall Street Zen downgraded shares of Intellia Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 8th. Wolfe Research cut shares of Intellia Therapeutics from a “peer perform” rating to an “underperform” rating and set a $9.00 target price for the company. in a research report on Wednesday, July 15th. Evercore upgraded shares of Intellia Therapeutics from a “hold” rating to an “outperform” rating and set a $24.00 target price for the company in a research report on Friday, August 7th. Barclays started coverage on shares of Intellia Therapeutics in a report on Tuesday, October 6th. They set an “underweight” rating and a $8.00 price target for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Intellia Therapeutics in a research report on Thursday, October 15th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, seven have issued a Hold rating and four have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $21.44.

Get Our Latest Report on NTLA

Intellia Therapeutics Stock Up 2.1%

NTLA stock opened at $11.41 on Tuesday. The business has a 50-day simple moving average of $12.02 and a 200 day simple moving average of $13.00. Intellia Therapeutics has a 52 week low of $7.95 and a 52 week high of $18.48.

Hedge Funds Weigh In On Intellia Therapeutics

A number of institutional investors have recently added to or reduced their stakes in NTLA. Nykredit A S bought a new position in Intellia Therapeutics in the 2nd quarter valued at approximately $33,000. Freestone Grove Partners LP acquired a new stake in Intellia Therapeutics in the second quarter valued at approximately $33,000. Integrated Wealth Concepts LLC acquired a new stake in Intellia Therapeutics in the second quarter valued at approximately $34,000. Farther Finance Advisors LLC grew its stake in shares of Intellia Therapeutics by 289.8% during the third quarter. Farther Finance Advisors LLC now owns 2,144 shares of the company’s stock worth $26,000 after buying an additional 1,594 shares during the last quarter. Finally, Parallel Advisors LLC grew its stake in shares of Intellia Therapeutics by 267.0% during the third quarter. Parallel Advisors LLC now owns 2,268 shares of the company’s stock worth $27,000 after buying an additional 1,650 shares during the last quarter. 88.77% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Intellia Therapeutics

In related news, CEO John M. Leonard sold 9,000 shares of Intellia Therapeutics stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $11.99, for a total transaction of $107,910.00. Following the sale, the chief executive officer directly owned 1,138,064 shares of the company’s stock, valued at approximately $13,645,387.36. The trade was a 0.78% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 3.50% of the company’s stock.

Key Stories Impacting Intellia Therapeutics

Investors following NTLA have been watching these stories:

  • Positive Sentiment: HC Wainwright reiterated its “Buy” rating and $25 price target, well above the share price cited in the background, despite trimming its earnings estimates. Intellia Therapeutics analyst coverage
  • Neutral Sentiment: Intellia is scheduled to present at the Jefferies Global Healthcare Conference in London, which may give investors an opportunity to hear company updates, but no new information was reported in the announcement. Conference announcement
  • Negative Sentiment: HC Wainwright lowered its 2026 and 2027 earnings estimates, while Brookline Capital Markets cut its 2026 estimates and reduced projected 2029–2030 EPS. The revisions point to weaker expected earnings, even though the company is still forecast to report losses in the near term. Intellia Therapeutics analyst coverage

Intellia Therapeutics Company Profile

(Get Free Report)

Intellia Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing genome-editing treatments for serious diseases. Founded in 2014 and headquartered in Cambridge, Massachusetts, the company uses CRISPR/Cas9 technology to make targeted changes to DNA. Its research includes in vivo therapies, which are designed to edit genes inside a patient’s body, and ex vivo approaches, which involve modifying cells outside the body before they are returned to the patient. Intellia’s investigational programs have included treatments for transthyretin amyloidosis and hereditary angioedema.

Featured Articles

Earnings History and Estimates for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.